HAIFA, Israel, May 5, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (DAX:PJT) (TASE:PLTR), announced today that over the next two months, company executives will be presenting at four leading industry events. The presentations follow the completion of six-month follow-up on patients treated with the Company's Critical Limb Ischemia therapeutic, PLX-PAD.
"As part of our ongoing clinical, scientific and financial progress, we are pleased to be invited to present at a variety of financial and scientific conferences," said Zami Aberman, Chairman and Chief Executive Officer of Pluristem. "These presentations will enable us to discuss the competitive advantages of our platform, as well as our planned product portfolio, with a number of strategic target audiences."
Phase I clinical trials suggest that Pluristem's placenta-derived cell therapy, PLX-PAD, is safe, improves quality of life, and is potentially effective in treating patients and reducing amputation rate in those suffering from Critical Limb Ischemia (CLI), the end-stage of Peripheral Artery Disease (PAD). Among the 27 patients treated with PLX-PAD, no mortality events and only one amputation were recorded, representing a 3.7% amputation rate. This represents a 75% reduction in amputation rate compared to historical data, which varies between 20-40%.
Over the next two months, Pluristem will be presenting at the following conferences:
About Pluristem Therapeutics Inc.
Pluristem Therapeutics Inc. (Nasdaq:PSTI) (DAX:PJT) is a leading developer of placenta-based cell therapies. The company's patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an off-the-shelf product that requires no tissue matching prior to administration. Data from two phase I studies indicate that Pluristem's first PLX product, PLX-PAD, is safe and potentially effective for the treatment of end stage Peripheral Artery Disease. Pluristem's pre-clinical animal models have demonstrated PLX cells are also potentially effective in nerve pain and muscle damage, when administered locally, and in inflammatory bowel disease, MS and stroke, when administered systemically.
Pluristem has a strong patent portfolio, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team.
For more information visit , the content of which is not part of this press release. Follow Pluristem on Twitter @Pluristem.
The Pluristem Therapeutics Inc. logo is available at
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, we are using forward looking statements when we speak about the competitive advantages of our platform, or when we say that Phase I clinical trials suggest that our placenta-derived cell therapy, PLX-PAD, is safe, improves quality of life, and is potentially effective in treating patients and reducing amputation rate in those suffering from Critical Limb Ischemia (CLI), or when we say that Pluristem's pre-clinical animal models have demonstrated PLX cells are also potentially effective in nerve pain and muscle damage when administered locally and in inflammatory bowel disease, MS and stroke when administered systemically, or when we say that we have a strong patent portfolio. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching our clinical trials; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.
CONTACT: Pluristem Therapeutics Inc. William Prather R.Ph., M.D. Sr. VP Corporate Development 1-303-883-4954 William.PratherMD@pluristem.com Daya Lettvin Director Investor & Media Relations +972-54-674-5580 firstname.lastname@example.org Media Contact: Matthew Krieger Ruder Finn - for Pluristem +972-54-467-6950 email@example.com